Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
27.09
+0.05 (0.18%)
At close: Mar 9, 2026, 4:00 PM EDT
27.40
+0.31 (1.14%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Surrozen Revenue
Surrozen had revenue of $983.00K in the quarter ending September 30, 2025, a decrease of -90.17%. This brings the company's revenue in the last twelve months to $3.60M, down -63.96% year-over-year. In the year 2024, Surrozen had annual revenue of $10.66M.
Revenue (ttm)
$3.60M
Revenue Growth
-63.96%
P/S Ratio
70.88
Revenue / Employee
$87,902
Employees
41
Market Cap
252.55M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fennec Pharmaceuticals | 38.79M |
| Alector | 21.05M |
| Sol-Gel Technologies | 18.97M |
| Prelude Therapeutics | 10.50M |
| Cibus | 3.79M |
| Orchestra BioMed Holdings | 2.82M |
| Humacyte | 1.57M |
| Inhibikase Therapeutics | 1.00 |
SRZN News
- 12 days ago - Surrozen to Present at Upcoming Healthcare Investor Conference - GlobeNewsWire
- 14 days ago - Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Surrozen to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 4 months ago - Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 months ago - Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 10 months ago - Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway - GlobeNewsWire
- 10 months ago - Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire